A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort
Palbociclib and Ribociclib demonstrated comparable efficacy and safety profiles in this Indian cohort. While no statistically significant differences in PFS or OS were observed, the data suggest a marginal survival benefit with Ribociclib. These findings underscore the importance of individualized treatment plans in HR+/HER2- breast cancer, taking into consideration patient-specific factors. Larger studies with longer follow-up are needed to further clarify the nuances between these two agents.
Authors
- M. R. Kaushik
- Rajesh Nair
- Amul Kapoor (ORCID: https://orcid.org/0000-0002-8589-2049)
- Dipen Bhuva (ORCID: https://orcid.org/0000-0002-8982-6209)
- Manish Kumar (ORCID: https://orcid.org/0000-0002-3931-3536)
- Nihanthy D. Sreenath (ORCID: https://orcid.org/0000-0002-6126-4005)
- Anvesh Rathore (ORCID: https://orcid.org/0000-0002-3108-5866)
- Rajath Govind (ORCID: https://orcid.org/0000-0002-3573-0420)
- Deepak Mulajker (ORCID: https://orcid.org/0000-0001-9775-0032)
- Suresh Pandalanghat (ORCID: https://orcid.org/0000-0002-7279-9881)
Institutions
- INHS Asvini (IN)
- Colorado Blood Cancer Institute (US)
- Saroj Gupta Cancer Centre & Research Institute (IN)
- Command Hospital (IN)
- Army Hospital Research and Referral (IN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1186/s12885-025-14270-1
- Citations
- 2
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 3.04